AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23376894 — intervention group
Group type: COMPARATOR
Intervention: Proclear Multifocal +2.00 diopters Add D (MF) soft contact lenses
Number of subjects: 24
Study 20471706 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin treatment
Number of subjects: 938
Study 19480865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of inspiratory and expiratory devices, training group (16 patients)
Number of subjects: 32
Study 19480865 — intervention group
Group type: COMPARATOR
Intervention: Sham training control group (16 patients)
Number of subjects: 32
Study 17064903 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching within arm's length
Number of subjects: 0
Study 17064903 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching beyond arm's length
Number of subjects: 0
Study 17064903 — intervention group
Group type: COMPARATOR
Intervention: Movement velocity
Number of subjects: 0
Study 17064903 — intervention group
Group type: COMPARATOR
Intervention: Final joint configuration
Number of subjects: 0
Study 17064903 — intervention group
Group type: EXPERIMENTAL
Intervention: Center of mass analysis during reaching
Number of subjects: 0
Study 15157793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preabortion counseling (intervention group)
Number of subjects: 420
Study 15157793 — intervention group
Group type: COMPARATOR
Intervention: No preabortion counseling (control group)
Number of subjects: 420
Study 10769857 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N2O/O2
Number of subjects: 19
Study 10769857 — intervention group
Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 19
Study 9314793 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR with social support intervention
Number of subjects: 337
Study 9314793 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 337
Study 9314793 — intervention group
Group type: COMPARATOR
Intervention: CPR only
Number of subjects: 337
Study 9314793 — intervention group
Group type: COMPARATOR
Intervention: CPR with cardiac risk factor education
Number of subjects: 337
Study 8154254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with adrenaline, bupivacaine with adrenaline, and hyaluronidase
Number of subjects: 139
Study 8154254 — intervention group
Group type: COMPARATOR
Intervention: Other tested mixtures (without hyaluronidase)
Number of subjects: 139
Study 3538753 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (200 mg increasing to 600 mg daily over 9 days)
Number of subjects: 65
Study 3538753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 3538753 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 65
Study 30031787 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity during both periods (prenatal and infancy)
Number of subjects: 412
Study 30031787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal food insecurity
Number of subjects: 412
Study 28532406 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin/Metformin therapy (n = 40)
Number of subjects: 60
Study 28532406 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (n = 20)
Number of subjects: 60
Study 27128001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (strong CYP3A4 inhibitor)
Number of subjects: 3
Study 27128001 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (weak CYP3A4 inhibitor)
Number of subjects: 3
Study 27128001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (CYP3A4 inducer)
Number of subjects: 3
Study 27128001 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (as an inhibitor of CYP3A4)
Number of subjects: 3
Study 23997106 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 12
Study 21146637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 92
Study 21146637 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 92
Study 21146637 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo
Number of subjects: 92
Study 21146637 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin placebo
Number of subjects: 92
Study 21146637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Simvastatin
Number of subjects: 92
Study 21146637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 21146637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 92
Study 19064627 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 894
Study 19064627 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 894
Study 16934158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at 12-hour intervals for 24 hours
Number of subjects: 73
Study 16934158 — intervention group
Group type: COMPARATOR
Intervention: Loose combination of artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP l) administered at 24-hour intervals for 3 days
Number of subjects: 73
Study 16934158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (AS+SMP f and AS+SMP l)
Number of subjects: 73
Study 12663967 — intervention group
Group type: EXPERIMENTAL
Intervention: Talent LPS stent graft
Number of subjects: 240
Study 12663967 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical repair
Number of subjects: 240
Study 10633973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for one week and 40 mg/day thereafter (group I)
Number of subjects: 57
Study 10633973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day (group II)
Number of subjects: 57
Study 10633973 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (group I)
Number of subjects: 57
Study 10633973 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (group II)
Number of subjects: 57
Study 8607401 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (5 to 10 mg/day)
Number of subjects: 60
Study 8607401 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 to 100 mg/day)
Number of subjects: 60
Study 8607401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8607401 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril and Metoprolol
Number of subjects: 60
Study 8607401 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-myocardial infarction patients
Number of subjects: 60
Study 8607401 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 60
Study 1901181 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 100
Study 1901181 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate tablets
Number of subjects: 100
Study 7083734 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg)
Number of subjects: 59
Study 7083734 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg)
Number of subjects: 59
Study 7083734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 30586694 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily for 16 weeks
Number of subjects: 226
Study 30586694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 30586694 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 226
Study 28765326 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) monotherapy (75 mg/m2 × 7 days every 28 days)
Number of subjects: 259
Study 28765326 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (AZA) combined with Vorinostat (VOR) (300 mg twice a day on days 3 to 9)
Number of subjects: 259
Study 26621626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral lateral ventricular size (graded on a 0 to 9 scale)
Number of subjects: 79
Study 26621626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical sulcal width (graded on a 0 to 9 scale)
Number of subjects: 79
Study 26621626 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH) (graded on a 0 to 9 scale)
Number of subjects: 79
Study 26621626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiles of ventricular size
Number of subjects: 79
Study 26621626 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of new ischemic lesions
Number of subjects: 79
Study 23229237 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine alcohol base mouthrinse (CLX-A)
Number of subjects: 30
Study 23229237 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Chlorhexidine non-alcohol base with 0.1% Formaldehyde (CLX-F)
Number of subjects: 30
Study 23229237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 30
Study 21507715 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib (1.3 mg/m2, twice per week)
Number of subjects: 222
Study 21507715 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bortezomib (1.3 mg/m2, twice per week)
Number of subjects: 222
Study 21507715 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Number of subjects: 222
Study 21507715 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bortezomib
Number of subjects: 222
Study 19623185 — intervention group
Group type: COMPARATOR
Intervention: Nutrition intervention component including modifications to the total school food environment, such as federal breakfast, lunch, after school snack and supper programs, a la carte venues, vending machines, and classroom parties.
Number of subjects: 42
Study 16436397 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐2‐3 Smokefree programme (video based internet site with tailored strategies)
Number of subjects: 351
Study 16436397 — intervention group
Group type: COMPARATOR
Intervention: Control group (received nothing for 90 days)
Number of subjects: 351
Study 16436397 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐2‐3 Smokefree programme (using intent-to-treat model)
Number of subjects: 351
Study 16436397 — intervention group
Group type: COMPARATOR
Intervention: Control group (using intent-to-treat model)
Number of subjects: 351
Study 15229342 — intervention group
Group type: EXPERIMENTAL
Intervention: eDiets.com (commercial Internet weight loss program)
Number of subjects: 47
Study 15229342 — intervention group
Group type: COMPARATOR
Intervention: Weight loss manual (LEARN Program for Weight Control 2000)
Number of subjects: 47
Study 15229342 — intervention group
Group type: EXPERIMENTAL
Intervention: eDiets.com
Number of subjects: 47
Study 15229342 — intervention group
Group type: COMPARATOR
Intervention: Weight loss manual
Number of subjects: 47
Study 11993078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockade (ICB) with ropivacaine 1% (4 times 5 ml)
Number of subjects: 43
Study 11993078 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with 7.5 mg piritramid i.v. before extubation and continuing with 2 mg boli and a 10 min lockout
Number of subjects: 43
Study 11993078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockade (ICB)
Number of subjects: 43
Study 11993078 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 43
Study 11993078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICB and PCA
Number of subjects: 43
Study 11993078 — intervention group
Group type: EXPERIMENTAL
Intervention: ICB
Number of subjects: 43
Study 11993078 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 43
Study 9808415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 61
Study 9808415 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 61
Study 9808415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 8553906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2 (18 million IU/day subcutaneously for 3 days)
Number of subjects: 30
Study 8553906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (6 million IU/day subcutaneously for 5 days) plus MLT (40 mg/day orally)
Number of subjects: 30
Study 8553906 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 30
Study 2220646 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 607
Study 2220646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study 719572 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 35
Study 7058754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 30 mg
Number of subjects: 12
Study 7058754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 60 mg
Number of subjects: 12
Study 7058754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg
Number of subjects: 12
Study 7058754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 15 mg (four times daily)
Number of subjects: 12
Study 7058754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 30 mg (four times daily)
Number of subjects: 12
Study 7058754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (various doses)
Number of subjects: 12
Study 7058754 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study 30669825 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth therapy
Number of subjects: 50
Study 30669825 — intervention group
Group type: COMPARATOR
Intervention: Classic anti-gravitation exercises
Number of subjects: 50
Study 29125382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Number of subjects: 166
Study 29125382 — intervention group
Group type: COMPARATOR
Intervention: Extra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Number of subjects: 166
Study 25984794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) after 8 sessions
Number of subjects: 581
Study 24452845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video gaming
Number of subjects: 20
Study 24452845 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 20
Study 22480620 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections into plantar flexor muscles
Number of subjects: 15
Study 22480620 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injections
Number of subjects: 15
Study 20414723 — intervention group
Group type: EXPERIMENTAL
Intervention: Filmed contact
Number of subjects: 143
Study 20414723 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of auditory hallucinations
Number of subjects: 143
Study 20414723 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 143
Study 17612811 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Piano Instruction (IPI)
Number of subjects: 31
Study 17612811 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 31
Study 16132480 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 56
Study 16132480 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 56
Study 16132480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 11804663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (40 g/day) for 4 weeks
Number of subjects: 5
Study 11804663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol withdrawal
Number of subjects: 5
Study 11804663 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic liver disease patients
Number of subjects: 5
Study 10416728 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 10416728 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 7487127 — intervention group
Group type: EXPERIMENTAL
Intervention: Azasetron (10 mg/day)
Number of subjects: 0
Study 7487127 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (3 mg/day)
Number of subjects: 0
Study 2148146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-oestrogen combined pill
Number of subjects: 68
Study 2148146 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only pill
Number of subjects: 68
Study 2148146 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 68
Study 7190495 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid air (80‐90% R.H.) during swimming
Number of subjects: 9
Study 7190495 — intervention group
Group type: COMPARATOR
Intervention: Dry air (15‐35% R.H.) during swimming
Number of subjects: 9
Study 7190495 — intervention group
Group type: COMPARATOR
Intervention: Treadmill run with room air dried to 25‐30% R.H.
Number of subjects: 9
Study 29254414 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 59
Study 29254414 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 59
Study 29254414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacology (PH)
Number of subjects: 59
Study 28166190 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed/suspended Stribild + enteral nutrition
Number of subjects: 24
Study 28166190 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed/suspended Stribild + breakfast
Number of subjects: 24
Study 28166190 — intervention group
Group type: COMPARATOR
Intervention: Whole Stribild tablet with breakfast (reference)
Number of subjects: 24
Study 26530649 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM THA
Number of subjects: 93
Study 26530649 — intervention group
Group type: COMPARATOR
Intervention: MoP THA
Number of subjects: 93
Study 26530649 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM THA (women)
Number of subjects: 93
Study 26530649 — intervention group
Group type: COMPARATOR
Intervention: MoP THA (women)
Number of subjects: 93
Study 26530649 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM THA (men)
Number of subjects: 93
Study 26530649 — intervention group
Group type: COMPARATOR
Intervention: MoP THA (men)
Number of subjects: 93
Study 26530649 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM THA (elevated cobalt levels)
Number of subjects: 93
Study 23547240 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5-20 mg/d)
Number of subjects: 21
Study 23547240 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100-300 mg/d)
Number of subjects: 21
Study 21486442 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Relative Total Dose Intensity (RTDI)
Number of subjects: 933
Study 21486442 — intervention group
Group type: EXPERIMENTAL
Intervention: RTDI cut-off levels <85%
Number of subjects: 933
Study 21486442 — intervention group
Group type: EXPERIMENTAL
Intervention: RTDI above 85%
Number of subjects: 933
Study 21486442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower RTDI
Number of subjects: 933
Study 19222455 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA patch-PDT
Number of subjects: 449
Study 19222455 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 449
Study 19222455 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 449
Study 17719935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 96
Study 17719935 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 96
Study 15592731 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/d
Number of subjects: 32
Study 15592731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11553421 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention designed to improve self-management ability
Number of subjects: 0
Study 11553421 — intervention group
Group type: COMPARATOR
Intervention: Urban residents
Number of subjects: 0
Study 9395036 — intervention group
Group type: EXPERIMENTAL
Intervention: CALGB trials
Number of subjects: 9
Study 7967349 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (0.5 ng/kg/min)
Number of subjects: 7
Study 7967349 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (1.0 ng/kg/min)
Number of subjects: 7
Study 7967349 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (2.5 ng/kg/min)
Number of subjects: 7
Study 7967349 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker (nifedipine) pretreatment
Number of subjects: 7
Study 3302010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1g twice daily
Number of subjects: 84
Study 3302010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 3302010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 84
Study 30782617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-fat diet (20% energy from fat)
Number of subjects: 217
Study 30782617 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-fat diet (40% energy from fat)
Number of subjects: 217
Study 30782617 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat diet (30% energy from fat)
Number of subjects: 217
Study 28236919 — intervention group
Group type: COMPARATOR
Intervention: Tunneled central venous catheters (TCVC)
Number of subjects: 121
Study 28236919 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cannulation arteriovenous grafts (ecAVG) with or without arteriovenous fistula (AVF)
Number of subjects: 121
Study 28236919 — intervention group
Group type: COMPARATOR
Intervention: Cost comparison between TCVC and ecAVG
Number of subjects: 121
Study 26129694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Cognitive Therapy (PCT)
Number of subjects: 0
Study 26129694 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0
Study 23527868 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intoxicating dose of alcohol (mean blood alcohol concentration = 0.076 g/dl)
Number of subjects: 40
Study 23527868 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 40
Study 19819688 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (Group A)
Number of subjects: 108